Literature DB >> 526400

Acute management of severe hypertension with oral labetalol.

R R Ghose.   

Abstract

1 Six previously untreated emergency admissions to hospital with severe hypertension were given oral treatment with labetalol. 2 Pre-treatment diastolic BP exceeded 130 mmHg, and clinical evidence of either accelerated hypertension or encephalopathy was present. 3 Hypotensive response after treatment followed two patterns. 4 Quick-responders (n = 3) showed a sharp fall in BP to normal levels within 2 h, which was subsequently sustained for 10 or more hours. The daily dose of labetalol eventually required to achieve good BP control in this group was relatively low: 600--1200 mg. 5 Slow-responders (n = 3) showed a gradual, less marked fall in BP, which was sustained for many hours. These patients required further doses of labetalol to reduce BP to normal. The eventual daily dose of labetalol that ensured good BP control was high: 1200--2400 mg. 6 Heart rate was little changed by treatment. 7 Complications or side-effects were not observed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526400      PMCID: PMC1429758     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Rapid onset of action of oral labetalol in severe hypertension.

Authors:  R R Ghose; A Sampson
Journal:  Curr Med Res Opin       Date:  1977       Impact factor: 2.580

2.  Primary hypertension refractory to triple drug treatment: a study on central and peripheral hemodynamics.

Authors:  O Andersson; L Hansson; R Sivertsson
Journal:  Circulation       Date:  1978-10       Impact factor: 29.690

3.  Treatment of hypertensive emergencies with oral labetalol.

Authors:  R R Ghose; Y B Mathur; M Upadhyay; W D Morgan; S Khan
Journal:  Br Med J       Date:  1978-07-08

4.  Study of untreated hypertensive subjects by means of continuous intra-arterial blood pressure recordings.

Authors:  A D Goldberg; E B Raftery; P M Cashman; F D Stott
Journal:  Br Heart J       Date:  1978-06

5.  Rate of onset of hypotensive effect of oral labetalol.

Authors:  M J Serlin; M C Orme; M Maciver; G J Green; C M Macnee; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

6.  Metabolism of labetalol by animals and man.

Authors:  L E Martin; R Hopkins; R Bland
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

  6 in total
  5 in total

1.  Medical management of dissecting thoracic aneurysms.

Authors:  P J Hogan
Journal:  Tex Heart Inst J       Date:  1990

2.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 4.  Hypertensive crises: emergencies and urgencies.

Authors:  Donald G Vidt
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-09       Impact factor: 3.738

Review 5.  Emergency room management of hypertensive urgencies and emergencies.

Authors:  D G Vidt
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 May-Jun       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.